Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ONCOCYTE CORPORATION

(OCX)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe BZX - 01/21 03:02:05 pm
1.675 USD   -9.95%
01/19AFTER HOURS WATCH LIST SCORECARD : Vero, rvnc, ocx
MT
01/19Oncocyte Shares Drop 11% After Marketing Deal With Thermo Fisher
DJ
01/18MT NEWSWIRES AFTER HOURS WATCH LIST : Vero, rvnc, ocx
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Cuts OncoCyte's Price Target to $7 From $8 on Lower Revenue Estimates; Buy Rating Kept

11/10/2021 | 05:57am EST


ę MT Newswires 2021
All news about ONCOCYTE CORPORATION
01/19AFTER HOURS WATCH LIST SCORECARD : Vero, rvnc, ocx
MT
01/19Oncocyte Shares Drop 11% After Marketing Deal With Thermo Fisher
DJ
01/18MT NEWSWIRES AFTER HOURS WATCH LIST : Vero, rvnc, ocx
MT
01/18OncoCyte Strikes Deal with Thermo Fisher to Expand Access to Precision Oncology
MT
01/18ONCOCYTE : Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific ..
PU
01/18ONCOCYTE CORP : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Fina..
AQ
01/18Oncocyte Corporation Enters into A Collaboration Agreement with Life Technologies Corpo..
CI
01/18Oncocyte Announces Development and Co-Marketing Agreement with Thermo Fisher Scientific..
GL
01/07Stephens Initiates OncoCyte With Overweight Rating, $3.10 Price Target
MT
01/07Stephens Starts OncoCyte at Overweight With $3.10 Price Target
MT
More news
Analyst Recommendations on ONCOCYTE CORPORATION
More recommendations
Financials (USD)
Sales 2021 7,67 M - -
Net income 2021 -40,0 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,17x
Yield 2021 -
Capitalization 172 M 172 M -
Capi. / Sales 2021 22,4x
Capi. / Sales 2022 11,7x
Nbr of Employees 51
Free-Float 89,8%
Chart ONCOCYTE CORPORATION
Duration : Period :
OncoCyte Corporation Technical Analysis Chart | OCX | US68235C1071 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 1,86 $
Average target price 6,46 $
Spread / Average Target 247%
EPS Revisions
Managers and Directors
Ronald Asbury Andrews President, Chief Executive Officer & Director
Mitchell Stuart Levine Chief Financial Officer
Cavan M. Redmond Chairman
Douglas T. Ross Chief Science Officer
Gisela Paulsen Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
ONCOCYTE CORPORATION-14.29%172
GILEAD SCIENCES, INC.-6.61%85 060
REGENERON PHARMACEUTICALS-2.71%64 237
VERTEX PHARMACEUTICALS4.10%58 125
WUXI APPTEC CO., LTD.-9.18%51 206
BIONTECH SE-39.28%37 805